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Abstract
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome,
which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare. We
assessed HRQOL by EQ-5D questionnaire at initial diagnosis in 1690 consecutive IPSS-Low/Int-1 MDS patients from the
European LeukemiaNet Registry. Impairments were compared with age- and sex-matched EuroQol Group norms. A
significant proportion of MDS patients reported moderate/severe problems in the dimensions pain/discomfort (49.5%),
mobility (41.0%), anxiety/depression (37.9%), and usual activities (36.1%). Limitations in mobility, self-care, usual
activities, pain/discomfort, and EQ-VAS were significantly more frequent in the old, in females, and in those with high co-
morbidity burden, low haemoglobin levels, or red blood cells transfusion need (p < 0.001). In comparison to age- and sex-
matched peers, the proportion of problems in usual activities and anxiety/depression was significantly higher in MDS
patients (p < 0.001). MDS-related restrictions in the dimension mobility were most prominent in males, and in older people
(p < 0.001); in anxiety/depression in females and in younger people (p < 0.001); and in EQ-VAS in women and in persons
older than 75 years (p < 0.05). Patients newly diagnosed with IPSS lower-risk MDS experience a pronounced reduction in
HRQoL and a clustering of restrictions in distinct dimensions of HRQoL as compared with reference populations.
Introduction
Myelodysplastic syndromes (MDS) represent challenging
hematopoietic disorders characterized by cytopenias, func-
tional blood defects, and clonal hematopoiesis. The clinical
course is characterized by an impaired health-related quality
of life (HRQoL), the risk of transformation to acute myeloid
leukaemia (AML) and reduced survival in the majority of
patients [1]. Based on biological parameters, the patients are
classified into different risk groups to predict overall
survival (OS) and the risk of AML transformation. The
international prognostic scoring system (IPSS) [2] and more
recently, the revised IPSS (IPSS-R) [3] represent the gold
standard in prognostication of MDS. Based on these scoring
systems, IPSS low/intermediate-1 risk and IPSS-R (very)
low/intermediate risk are classified as lower-risk MDS with
a low propensity to transform to AML [2, 3]. The treatment
goals in this cohort of patients are an improvement in
cytopenias, prolongation of survival, and improvement and
maintenance of HRQoL and functional capacities. IPSS
intermediate-2/high and IPSS-R high/very high risk are
classified as higher-risk MDS, which are characterized by
an increased risk of AML transformation and a short
median survival of less than 2 years [1].
Patients with MDS often suffer from a high symptom
burden, resulting in restrictions in HRQoL. Assesssment of
HRQoL provides information on the patient´s perspective
and perception, thus representing a relevant patient-reported
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outcome (PRO) [1, 4, 5]. The study of HRQoL has become
an increasingly critical area of research [6], as limitations in
HRQoL are frequently observed in MDS and are only
partially explained by anaemia [7, 8]. Moreover, restrictions
in HRQoL may predict an unfavourable clinical outcome
[9–12]. In addition HRQoL represents a parameter of
response evaluation [1, 13, 14]. Thus, the integration of
assessment of HRQoL in MDS has been propagated by
clinicians, stakeholders, and authorities [1, 13–15]. How-
ever, definitive data on HRQoL in low-risk MDS at initial
diagnosis are limited by small sample size [16, 17], selec-
tion bias [7, 16, 17], and assessment later after initial
diagnosis [7, 11, 16, 18, 19]. In addition, most studies have
included patients with higher-risk MDS [9–12, 16, 18–20],
AML [10, 11], or CMML [11, 16], which precludes precise
interpretation. Lower-risk patients with MDS are typically
of advanced age with a median of 74 years at diagnosis
[21]. The dissection between age-associated restrictions in
HRQoL and the incremental impact of MDS in these
patients is relevant, yet has not been analyzed at all.
The main objective of this international prospective cohort
observational study is to investigate the HRQoL profile of
patients with lower-risk MDS at the time of diagnosis, as
compared with the general population matched on age and
sex. The incremental impact of MDS on symptom burden is
dissected by comparing features in MDS with the general
population. A secondary objective is to examine clinical
factors associated with HRQoL of these patients.
Materials/methods
Participants
The EUMDS Registry is a prospective, non-interventional
longitudinal study, enroling newly diagnosed patients with
IPSS low or intermediate-1 MDS from 145 haematology
centres in 17 European countries and Israel. Patients with an
IPSS risk intermediate-2 or high, or with therapy-related
MDS were excluded. Patients without cytogenetic infor-
mation were only included if the diagnosis of MDS was
morphologically proven, with <5% bone marrow blasts and
at most a single cytopenia according to the IPSS. Based on
these criteria, exclusively IPPS low or intermediate-1
patients were included in EUMDS.
Therapy is given according to local guidelines [21].
Enrolment was within 100 days of the diagnostic bone marrow
aspirate. The average time from date of diagnosis to inclusion
was 44 days (standard deviation 28 days). Details on design
and data collection have been published elsewhere [21].
As the European Quality of Life five Dimensions (EQ-
5D) was not licensed in two countries, 15 countries were
included in this analysis. EUMDS (ClinicalTrials.gov:
NCT00600860) has been approved by the ethics commit-
tees of all participating centres and is performed in accor-
dance with the Declaration of Helsinki. Written informed
consent was obtained from all patients.
HRQoL measurement
Patient-reported HRQoL was measured by EQ-5D, at the
time of study enrolment. EQ-5D is a validated, generic,
HRQoL questionnaire [22], consisting of the EQ-5D
descriptive system with five dimensions related to daily
activities (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression), with three-level answers (no
problem, some problems, severe problems), and a visual
analogue scale (EQ-VAS). The five dimensions were con-
verted into a single summary index (EQ-5D index) by
applying the European value set (EVS) [23]. EQ-VAS [22]
is a global evaluation of ‘own health today’ using a health
state scale ranging from 0 (worst imaginable) to 100 (best
imaginable).
Measures of population norms
The main objective of this paper was to compare the QoL of
patients with MDS with general population with a similar
age and gender distribution. Therefore, population norms
were used as reference values to assess the relative HRQoL
of patients in comparison to that of an average person [24].
Population norms are based on descriptions of current
health status from population surveys. Nine European
countries in this study (Denmark, France, Germany, Greece,
Italy, Netherlands, Spain, Sweden, and the UK) have
reported a series of tables of age/sex population norms for
the EQ-5D for both, profile data and VAS scores [25]. For
the five European countries and Israel for which there are no
published EQ-5D population norms, we replaced the
missing data on the probabilities of being in a given level
for each EQ-5D dimension with the mean of the available
European countries by matching the combination of age
group and gender.
Demographic and clinical parameters
Information on patients’ demographics (age and gender),
IPSS-R, co-morbidity index (MDS-CI), haemoglobin (Hb)
level at the time of diagnosis, and red blood cell transfu-
sions (RBCT) in the year prior to the diagnosis were
recorded [3, 21, 26]. Due to the small number of young
adult patients, age was categorized into three groups (<60,
60–75, and 75+ years) to compare HRQoL of different age
groups.
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Statistical analysis
Differences in response between the five EQ-5D dimensions
in patients with MDS and European norms were evaluated
using χ2 tests. For both EQ-5D index and EQ-VAS, the
mean score with standard deviation was calculated. Wil-
coxon’s signed ranks tests were conducted to identify any
major difference between the MDS patient baseline values
and European norms. The relationship between HRQoL and
demographic/clinical factors was examined using multilevel
linear regression (additional information is available
in Supplementary Materials); univariate analysis was per-
formed for age at diagnosis, gender, IPSS-R, MDS-CI, Hb,
and RBCT status, and a multivariate analysis was per-
formed adjusting for all other variables. We assessed the
discriminative ability of HRQoL not only by a significant
difference, but also by a minimally important difference
(MID) [27]. The MID is viewed as the smallest difference in
score in the domain of interest that is perceived by patients
as beneficial or that would result in a change in treatment.
See Supplementary Materials for more detail.
All analyses were undertaken in Stata 14 (StataCorp,
College Station, TX).
Results
Characteristics of patients
Based on IPSS-scoring, i.e., the gold-standard in classifica-
tion at the time of start of the registry, 1985 patients were
included between December 2007 and January 2016, among
which 961 (48.4%) were IPSS low-risk and 912 (45.9%)
were IPSS Int-1. IPSS score could not be calculated in 5.6%
of patients where cytogenetic testing was not available or had
failed. Based on inclusion criteria, exclusively IPSS low or
int-1 patients were included. Retrospective classification by
IPSS-R revealed a (very) low risk in 24.8% and 37.6%, an
intermediate risk in 21.2%, high/very high risk in 6.1%, and
classification was unknown in 10.3% of patients. In total,
1690 patients (85.1%) completed both EQ-5D descriptive
system and EQ-VAS. Thirty-three patients (1.7%) completed
EQ-5D description only, and seven patients (0.3%) com-
pleted EQ-VAS only (Table 1.). The majority of patients had
advanced age (median age: 74 years), and a male pre-
ponderance was observed. Nearly half of patients were
characterized by Hb levels <10 g/dL at baseline, and more
than 30% of patients had received RBCT within 1 year prior
to diagnosis. Demographic characteristics of the patients who
completed EQ-5D did not differ substantially from the total
cohort, showing a similar age distribution and a slightly
higher proportion of men. Overall, the HRQoL data in our
sample were likely missing at random (Table 1).
Patients with MDS reveal profound impairments in
HRQoL
The MDS cohort was characterized by a mean EQ-5D
index-score of 0.74 and a mean EQ-VAS of 69.6. A sig-
nificant proportion of MDS patients reported moderate or
severe problems in the dimensions pain/discomfort (49.5%),
mobility (41.0%), anxiety/depression (37.9%), and usual
activities (36.1%), respectively. The dimension with the
lowest proportion of restrictions was self-care (13.3%)
(Table 2). Clinically meaningful restrictions in the dimen-
sions mobility, self-care, usual activities, and pain/dis-
comfort as well as in EQ-VAS and EQ-5D index were
observed significantly more often in older patients and in
those with a high co-morbidity burden, low Hb-levels, or
RBCT need (p < 0.001). Increased problems with anxiety/
depression were significantly more frequent in women (p <
0.001) and in patients with lower Hb-levels (p < 0.01). The
impact of both of IPSS and IPSS-R on EQ-5D scoring was
only marginal. In general, restrictions in all parameters of
EQ-5D were significantly more often reported in female
patients (p < 0.05, Table 2).
Association of restrictions in HRQoL and
demographic and disease factors
To assess possible associations between clinical parameters
and HRQoL, univariate and multivariate linear analyses
were performed. It was estimated that patients in the
reference group of each of demographic and clinical para-
meters would have a mean score of 0.85 on the EQ-5D
index, and 80.85 on the EQ-VAS (Table 3). Relative to
these scores, there was a significant loss in HRQL for
groups who were older (e.g., 75+ vs. <60 years; index:
−0.08; VAS: −7.33), female, or had increased comorbid-
ities, low Hb-levels, or transfusion dependence (Table 3).
These differences exceeded the MID on each of the two
HRQL measures (>0.03 on the EQ-5D index and >3.0 on
the EQ-VAS). In summary, HRQoL as defined by EQ-5D
index and EQ-VAS was more often significantly impaired
in older and in female patients and in persons with advanced
comorbidities, low Hb levels, and increased transfusion
need both in uni- and in multivariate analyses.
Comparison of HRQoL in MDS and in age- and sex-
matched reference populations
We compared subgroups of MDS patients with age- and
sex-matched reference norms. Overall, patients with MDS
were characterized by a small, but significantly lower EQ-
5D index (0.74 vs. 0.76) and lower EQ-VAS (69.6 vs. 71.8)
than European norms (p < 0.05) (Table 4). However, these
differences were too small to fulfil the criteria of MID. In
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Table 1 Demographic and clinical characteristics of MDS-patients—entire cohort and EQ-5D respondents
Total EQ-5D Completeda EQ-5D not completed
Characteristic No. of Patients % No. of patients % No. of patients %
Entire cohort 1 985 100.0 1 690 85.1 295 14.9
Age, years
<60 214 10.8 187 11.1 27 9.2
60–75 818 41.2 707 41.8 111 37.6
75+ 953 48.0 796 47.1 157 53.2
Gender
Male 1 202 60.6 1 039 61.5 163 55.3
Female 783 39.4 651 38.5 132 44.7
Diagnosis (WHO 2001)
RA 355 17.9 283 16.7 72 24.4
RARS 310 15.6 276 16.3 34 11.5
RCMD 755 38.0 651 38.5 104 35.3
RCMD-RS 118 5.9 102 6.0 16 5.4
RAEB-1 239 12.0 207 12.2 32 10.8
RAEB-2 9 0.5 8 0.5 1 0.3
MDS-U 81 4.1 68 4.0 13 4.4
5q-Syndrome 118 5.9 95 5.6 23 7.8
IPSS
Low risk 961 48.4 813 48.1 148 50.3
Intermediate-1 912 45.9 782 46.3 130 43.9
Low/int-1 no cytogeneticsb 112 5.6 95 5.6 17 5.7
IPSS-R
Very low risk 493 24.8 433 25.6 60 20.3
Low risk 746 37.6 646 38.2 100 33.9
Intermediate risk 420 21.2 341 20.2 79 26.8
High/very high risk 121 6.1 110 6.5 11 3.7
Unknown 205 10.3 160 9.5 45 15.3
MDS-CI
Low risk 1 276 64.3 1 076 63.7 200 67.8
Intermediate risk 606 30.5 525 31.1 81 27.5
High risk 103 5.2 89 5.3 14 4.7
Haemoglobin (g/dL)
≥10 1 076 54.2 913 54.0 163 55.3
<10 884 44.5 768 45.4 116 39.3
Unknown 25 1.3 9 0.5 16 5.4
Red blood cell transfusionc
No 1 390 70.0 1 163 68.8 227 76.9
Yes 595 30.0 527 31.2 68 23.1
WHO World Health Organization, IPSS International Prognostic Scoring System, IPSS-R Revised International Prognostic Scoring System, MDS-
CI Myelodysplastic Syndrome-Comorbidity Index, HCT-CI Hematopoietic Cell Transplant-Comorbidity Index
a Includes EQ-5D completed only, EQ-VAS completed only, and both completed
b Patients with cytogenetics failed or not available were included if the diagnosis of MDS was morphologically proven, with <5% bone marrow
blasts and at most a single cytopenia according to the IPSS. Based on these criteria, exclusively IPPS low or int-1 patients were included in this
cohort
c As assessed in the year prior to initial diagnosis
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched. . . 1383
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contrast, distinct differences which fulfilled the criteria of a
MID were seen in individual components of EQ-5D: a
significantly higher proportion of MDS patients reported
moderate/severe problems in the dimensions mobility, usual
activities, and anxiety/depression compared to the reference
populations (p < 0.001) (Table 4).
Analyses stratified by sex and age depicted most pro-
nounced differences in the dimensions anxiety/depression,
and usual activities, in all age groups, and in both sexes
(p < 0.001). Compared to peers, prevalence of problems
in anxiety/depression was most prominent in female
(16.7% vs. 50.3%; Fig. 1b) and in younger patients
(9.8% vs. 40.8%, p < 0.001; Fig. 2a). Restrictions in
mobility were most pronounced in male (Fig. 1a) and in
older patients (60+ years; p < 0.01; Fig. 2c). The dimen-
sions self-care and pain/discomfort were not different
between the cohorts (Table 2; Figs. 1 and 2). Differences in
EQ-5D index were most pronounced in younger MDS
patients (<60 years). EQ-VAS was more often diminished at
advanced age (75+ years) as compared to peers
(p < 0.001; Table 2). These differences fulfilled the criteria
of a MID.
Discussion
This prospective cohort observational study adds substantial
information on the prevalence and clustering of restrictions
Fig. 1 Proportion of moderate/severe problems in male (a) and female
(b) patients with MDS (blue bars) as compared to European age- and
sex-matched standard population (dark grey). Standard errors indicated
as lines. Differences (Δ) of patients with MDS to sex-matched refer-
ence group shown when significant (*** p < 0.001; **p < 0.01; *p <
0.05; as assessed by Wilcoxon signed rank tests)
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in HRQoL in lower-risk patients with MDS at diagnosis. In
a cross-sectional analysis, we observed profound restric-
tions in distinct dimensions of the EQ-5D when compared
with European reference populations. Moreover, we iden-
tified demographic and clinical factors, which are associated
with restrictions in HRQoL.
Fig. 2 Proportion of moderate/
severe problems by age group
(<60 (a), 60–75 (b), or >75 (c)
years old) in patients with MDS
(blue bars) as compared to
European age- and sex-matched
standard population (dark grey).
Standard errors indicated as
lines. Differences (Δ) of patients
with MDS to sex-matched
reference group shown when
significant (***p < 0.001; **p <
0.01; *p < 0.05; as assessed by
Wilcoxon signed rank tests)
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Prevalence of restrictions in HRQoL in MDS at initial
diagnosis / Factors associated with decreased
HRQoL
Data on symptom burden in lower-risk MDS at initial
presentation are rare, and limited by small sample size [16,
17], selection bias [7, 16, 17], and analyses performed later
after initial diagnosis [7, 11, 16, 18, 19]. In addition, most
studies have included patients with higher risk MDS [9–11,
16, 18–20], AML [10, 11] or CMML [11, 16], which pre-
cludes precise interpretation. The strength of our study is
the large number of observations at initial diagnosis and the
parallel analysis of the different parameters of the validated
score EQ-5D including EQ-5D VAS, EQ-5D index as well
as the different EQ-5D dimensions in a homogenous cohort
of lower-risk patients. This is the first report to present
details on restrictions in the distinct domains of EQ-5D in
MDS, which reveals huge differences in HRQoL-profile in
daily activities. These findings are particularly relevant, as
studies from the literature reported exclusively EQ-5D
summary scores and EQ-5D VAS [16, 20], but lacked a
presentation of EQ-5D daily activities.
Our study shows a pronounced symptom burden in many
patients with MDS, predominantly in the dimensions pain/
discomfort, mobility, anxiety/depression, and usual activities.
Moreover, a clustering of symptoms in distinct subgroups of
patients is revealed. The low percentage of self-reported
problems in the dimension self-care, particularly in elderly is
remarkable. This phenomenon has been observed across
different cancer types [28] and may be explained by focusing
on “washing and dressing” in the definition of self-care,
whereas functional capacities like “work, housework, family
or leisure activities” are assessed in the dimension “usual
activities”.
We demonstrated that advanced age, pronounced
co-morbidities, low Hb-levels, RBCT need, and female sex
were significantly associated both with a decreased EQ-5D
index, and decreased EQ-VAS after adjustment for
co-variables. These observations extend data from the
literature [7, 8, 18, 20] and define cohorts of patients which
are at high risk of decreased HRQoL. Hb levels [7, 18, 20]
and transfusion dependence [20] are important predictors
of HRQoL, both in this study and in the literature.
Effective treatment for anaemia and reduction of transfusion
need might thus contribute to improvement and main-
tenance of HRQoL [17]. Future studies will focus on the
prediction of deterioration of HRQoL, and focus on early
prevention.
A relevant aspect of our work is the significant difference
in symptom burden in patients with MDS as compared to
age- and sex matched European reference populations.
Thus, dissection of features which are MDS-specific from
symptoms which are present in matched general
populations is possible. This study reveals an incremental
symptom burden in MDS characterized by pronounced age-
and sex-dependent differences in the distinct EQ-5D
dimensions. Both young and old patients suffer from trou-
blesome MDS-related symptoms. Data from the literature
are rare and have been characterized by a small sample size
and were restricted to one country [16, 17]. The study of
Hellstrom evaluated HRQoL at later time points after
diagnosis, and was focused on selecting anaemic patients
with a high probability for response to ESAs for a clinical
study [17]. The study of Jansen [16] reported exclusively
EQ-5D VAS but lacked a presentation of EQ-5D daily
activities for which we show strong differences. Moreover,
patients in Jansen's study were entered at variable time
points after diagnosis, and included patients with higher risk
MDS and CMML [16].
The high prevalence of anxiety/depression and of
limitations in usual activities is more pronounced in women
in our study. These observations form the basis to
appreciate the relevance of MDS on individual health in a
given patient and the opportunity to assist health care pro-
viders in managing the relevant symptoms [8]. Thus,
patient-centred care will be improved by special attention to
patient subgroups [29, 30]. The finding of the difference of
depression between our MDS patients and the general
population is corroborated by similar evidence in other
haematologic conditions. For example, Efficace et al. [31]
observed that depression was one of the most impaired
psychological domains in a sample of chronic myeloid
leukaemia patients as compared to their peers in the general
population; and, similar to our findings, this impairment
was most pronounced in female patients. In agreement with
other studies [8, 32, 33], differences by gender were
observed with lower HRQoL being more pronounced in
females. Although the discussion of causes of disparity in
gender-based distribution is beyond the scope of this
manuscript, gender-specific evaluations and interventions
should be discussed or suggested in patients with MDS.
The relevance of anxiety/depression in patients with MDS
is supported by the fact that 9.5% of EU-MDS patients
receive antidepressants at baseline [21], and that impairments
in depression screening by geriatric depression scale (GDS)
are observed in 24% of patients with MDS [34]. Likewise
“emotional health” and “uncertainty/sense of control” have
been highly ranked by patients and caregivers in a recent
study [35]. To address the individual needs of patients with
MDS, the novel, disease specific score for MDS, QUALMS
[18, 35], is currently applied and validated in the
EUMDS-cohort. Our study also confirms that age- and
sex-dependent baseline values in HRQoL should be
considered when interpreting the results of clinical studies
in MDS that use HRQoL as an endpoint, as suggested
recently [4, 8].
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Strengths of this work are the large number of observa-
tions, the well-defined inclusion criteria in a non-
interventional registry, the enclosure of newly diagnosed
MDS patients within 100 days of the date of the diagnostic
bone marrow aspirate, and the parallel analysis of the dif-
ferent parameters of the validated generic score EQ-5D
[21]. Based on the use of a generic questionnaire, com-
parisons with reference populations are possible.
Limitations: Disease-specific scores may more accurately
reflect the spectrum in a given disease. To address this
aspect, the MDS-specific score QUALMS has been devel-
oped recently [18, 35]. QUALMS has been integrated in
EUMDS in a recently amended version of the protocol.
Based on objectives of this study and the EUMDS registry,
analyses have been restricted to IPSS lower-risk MDS.
Therefore, this study does not allow conclusions on MDS in
general. However, the recently introduced new protocol of
the registry will register all subtypes of MDS. Other aspects
of HRQoL, which might be relevant for the outcome of
patients, e.g., the deterioration of HRQoL over time, have
not yet been analyzed. These investigations are currently
performed in several studies focusing on the impact of
specific interventions on HRQoL.
In summary
This is the first study to analyze prospectively the PRO
HRQoL in IPSS lower-risk MDS at diagnosis, and to
compare patients with MDS with age- and sex-matched
healthy populations. Patients experience profound age- and
sex-dependent restrictions in different HRQoL dimensions.
Distinct demographic and disease parameters are associated
with reduced HRQoL. These observations should form the
basis for individualized treatment directed at relief of dis-
tinct symptoms. In addition, these results may provide a
benchmark in the evaluation of new interventional options
aimed at improving HRQoL outcomes.
Supplementary Materials is available at Leukaemia
(www.nature.com/leu) providing additional information
regarding (i) EQ-5D index and EVS; (ii) on the comparison
of patients with MDS and the reference population; (iii) on
multivariate analysis; and (iiii) on minimally important
difference (MID).
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